GREGORY JOSEPH SIMMONS, M.D.

Plain English
This research paper looks at how technology can help people make healthier food choices while shopping for groceries. The authors reviewed 25 studies that explored various "nudging" techniques—like using apps or virtual reality to influence decisions—and found these methods can effectively encourage healthier eating habits. This is important because better food choices can help combat obesity, a major global health issue. Who this helps: This benefits consumers, particularly those trying to improve their diet and health.

Plain English
This study examined blood donors in Manaus, Brazil, during the Oropouche virus outbreak from 2023 to 2024. The researchers found that about 6.5% of blood donations tested positive for the virus, and the rate of immune response in donors nearly doubled, indicating around 390,000 infections occurred, which is much higher than the reported cases. This matters because it raises concerns about blood safety and the potential for the virus to spread through blood transfusions. Who this helps: This helps patients who may need blood transfusions, ensuring their safety from undetected infections.

Plain English
This study looked at how ruptured brain aneurysms are diagnosed, treated, and what happens to patients afterward in Africa, analyzing data from over a thousand patients across multiple studies. The findings revealed that most patients (75%) underwent surgical clipping, with about 67% showing improvement in their symptoms, while the death rate was around 12%. Understanding these details is important because it helps improve treatment approaches and outcomes for patients with this serious condition in Africa. Who this helps: This benefits patients with ruptured brain aneurysms and their healthcare providers.

Plain English
This study looked at how COVID-19 lockdowns affected injuries in children from wheeled recreational vehicles, like scooters and bicycles, in New South Wales, Australia. Researchers found that during lockdowns, 63% of the injuries (688 out of 1,098 cases) happened on weekdays, compared to only 52% during non-lockdown times. Understanding these changes helps us prepare better for future public health situations, especially regarding child safety and injury prevention. Who this helps: This benefits parents, doctors, and policymakers focused on child safety during emergencies.

Plain English
This study looked at how different types of viruses in coral reefs affect the growth of harmful bacteria. Researchers found that healthy reefs had viruses that kill bacteria and slow their growth, while degraded reefs had viruses that allow bacteria to grow faster. Specifically, the healthy reefs were linked to certain viral genes that support this "bacterial killing," while the degraded reefs had genes associated with boosting bacterial populations. Understanding how these viruses work is important because it can help us develop new ways to save declining coral reefs. Who this helps: This helps coral reef conservationists and marine biologists working to protect ocean ecosystems.

Plain English
This study looked at the effectiveness and safety of a cancer treatment called axicabtagene ciloleucel for patients with advanced large B-cell lymphoma who had not responded to previous therapies. Out of 30 patients treated, 93% had a positive response to the treatment, with 76% achieving complete remission. However, 90% experienced mild to moderate side effects like cytokine release syndrome, and 80% faced some neurological effects, although none were fatal, and most were manageable. Who this helps: This research benefits patients with relapsed large B-cell lymphoma looking for effective outpatient treatment options.

Plain English
This study looked at how well the CAR T-cell therapy called idecabtagene vicleucel (ide-cel) works for patients with multiple myeloma who also have kidney problems. Out of 214 patients, 28 had kidney issues, yet their responses to treatment were similar to those without kidney problems—93% of patients with kidney impairment responded to treatment compared to 82% without, and both groups had similar survival times. This is important because it shows that CAR T-cell therapy is safe and effective for patients with kidney issues, who often have fewer treatment options. Who this helps: Patients with multiple myeloma and kidney impairment.

Plain English
This study looked at patients with relapsed multiple myeloma receiving a specific CAR T-cell therapy called idecabtagene vicleucel (ide-cel). Of the 211 patients treated, 43 experienced disease progression or death within three months. Certain factors, like having extramedullary disease or a history of previous BCMA-targeted therapy, were linked to a higher chance of early progression, with those possessing three or more risk factors seeing a median progression-free survival of just 3.2 months compared to 14.1 months for those without these factors. Who this helps: This helps doctors identify patients who may need extra support and monitoring to improve their treatment outcomes.

Plain English
This study looked at how racial and ethnic differences affect the treatment outcomes of patients with multiple myeloma who received a specific therapy called CAR T-cell therapy. Researchers found that Black patients had higher levels of certain inflammation markers and were more likely to experience a serious side effect called cytokine release syndrome compared to Hispanic and White patients. Although the response rate to the treatment was lower for Hispanic patients at 59%, compared to 86% for both Black and White patients, all groups had similar overall survival rates. Who this helps: This research benefits patients with multiple myeloma, as well as their doctors, by highlighting the need for tailored treatment approaches.

Plain English
This study focused on a new toothbrush called the "ToothVac," which has a built-in vacuum to suck up saliva and other particles that can lead to lung infections when inhaled, especially in people who can't cough them out. In a trial with 18 participants, using the ToothVac reduced the amount of saliva produced during brushing. This matters because it could help lower the risk of aspiration pneumonia, a serious condition that can occur when particles enter the lungs. Who this helps: Patients at risk for aspiration pneumonia, especially those with difficulty expelling saliva.

Plain English
This study looked at how COVID-19 convalescent plasma (CCP) from recovered patients who were also vaccinated could affect hamsters infected with the virus. The researchers found that while this treatment temporarily made the hamsters sicker, it significantly reduced the amount of virus in their lungs and helped them recover faster. This is important because it suggests that using CCP from vaccinated individuals might be a beneficial treatment strategy for those infected with COVID-19. Who this helps: This helps COVID-19 patients, especially those who are severely ill.

Plain English
Researchers studied a compound called PAV-104 and its ability to stop the SARS-CoV-2 virus from replicating in human airway cells. They found that PAV-104 can block over 99% of SARS-CoV-2 infections, even from different variants, without affecting how the virus enters cells or makes its genetic material. This matters because it shows a new way to fight COVID-19 that could be more effective against evolving strains of the virus. Who this helps: This helps patients with COVID-19 and healthcare providers looking for effective treatments.

Plain English
This study looked at how the number of a specific type of white blood cell, called lymphocytes, affects the survival of patients with multiple myeloma who were treated with a therapy named idecabtagene vicleucel. Among the 214 patients analyzed, many had low lymphocyte counts before treatment, and those with low counts that decreased significantly had poorer outcomes, with only 40% remaining progression-free after six months, compared to over 60% for others. This information is important because it helps identify patients at higher risk for worse survival, allowing for better treatment decisions. Who this helps: This helps doctors identify which multiple myeloma patients may need closer monitoring and more aggressive treatment.

Plain English
This study evaluated different tests for detecting Zika virus (ZIKV) antibodies to improve diagnosis, especially in pregnant women, where it’s particularly tricky. They found that the tests for IgM antibodies varied widely in accuracy; only one test had both high sensitivity and specificity. While all IgG tests were generally sensitive, some incorrectly identified infections from other similar viruses as Zika, showing that getting accurate test results is complicated. Who this helps: This benefits pregnant women and healthcare providers involved in diagnosing and managing Zika virus infections.

Plain English
This research developed a system that uses advanced computer techniques to gather information about the relationships between foods and chemicals from a large number of scientific articles. The study successfully identified over 230,000 such relationships, with nearly half (106,082) not previously found in other databases. This new method will make it easier for researchers to discover important connections in food science, ultimately helping improve food safety and nutrition practices. Who this helps: Patients, food scientists, and nutritionists.

Plain English
Researchers studied how antibody levels change after people get infected with COVID-19 or vaccinated. They found that people who were infected and then vaccinated had higher antibody levels compared to those who were only vaccinated or infected without vaccination. Specifically, those with very high antibody levels (over 4000 BAU/mL) had a strong ability to neutralize the virus, giving hope for better sourcing of convalescent plasma for treatments. Who this helps: This benefits immunocompromised patients needing effective COVID-19 treatments.

Plain English
This study looked at how the Zika virus can be passed through blood transfusions by testing plasma from infected donors in mice and macaques. Researchers found that plasma could infect mice with as few as 32 units of viral RNA and showed that transfusions could lead to Zika virus transmission in macaques using doses between 50 and 5500 units. However, using a special treatment called PRT completely eliminated the risk of infection, even with large amounts of the virus. This is important because it helps ensure blood safety during Zika outbreaks, especially since there's currently no vaccine. Who this helps: Patients receiving blood transfusions during Zika outbreaks.

Plain English
This study looked at the real-world effects of a treatment called idecabtagene vicleucel (ide-cel) for patients with relapsed or refractory multiple myeloma, a type of blood cancer. It found that 84% of patients responded to the treatment, with 42% achieving a complete response, and average survival after treatment was about 12.5 months. This is important because it shows that ide-cel can work well even for patients who weren't eligible for earlier clinical trials, suggesting it could benefit a wider range of people with this condition. Who this helps: Patients with relapsed or refractory multiple myeloma.

Plain English
This study looked at how a specific sugar molecule on the surface of a human coronavirus called HCoV-NL63 affects the virus's ability to infect cells. Researchers found that a higher amount of this sugar, known as a glycan, makes HCoV-NL63 better at avoiding the immune system compared to SARS-CoV-2. The findings also indicated that the motion of the virus's spike protein, which helps it enter cells, is influenced by this glycan, making it a possible target for new treatments. Who this helps: This helps researchers and healthcare providers working on coronavirus treatments and vaccines.

Plain English
This study evaluated different tests used to detect the Zika virus to see how well they perform in clinical settings and blood screening. Researchers compared fifteen tests using a standard panel and found that most tests were fairly accurate, but there were some differences in their sensitivity and efficiency. Notably, tests designed for donor screening were more sensitive than those primarily for diagnosis, which is important for ensuring safe blood donations. Who this helps: This research benefits patients, especially pregnant women and those in areas at risk of Zika virus transmission.

Plain English
This study looked at how a protein called galectin-9 affects the replication of the virus that causes COVID-19 in airway cells. Researchers found that when these cells were treated with galectin-9, the virus replicated more effectively and triggered stronger inflammation, with specific increases in inflammatory signals like IL-6 and IL-8. This matters because understanding how galectin-9 helps the virus might lead to new treatments for COVID-19. Who this helps: This helps patients with COVID-19, especially those with severe cases.

Plain English
This study looked at how stereotactic radiosurgery (SRS), typically used for treating brain tumors, can also help with non-cancerous conditions like epilepsy, tremors, nerve pain, obsessive-compulsive disorder, and chronic pain. The authors found that while there isn’t much large-scale research, SRS can be beneficial for these disorders and could serve as a treatment option worth considering. This is important because it expands the ways to manage difficult-to-treat health issues. Who this helps: Patients with chronic, non-cancerous conditions may benefit from this treatment approach.

Plain English
This study looked at how the timing of immune system support after bone marrow transplants affects the recovery of T-cells, which are crucial for fighting infections. Researchers tested two different treatment plans in 26 patients: one where immune suppression lasted 30 days and another where it lasted 15 days, finding that the shorter suppression (MMF15 group) led to faster and more varied T-cell recovery. Specifically, T-cell recovery in this group was better during the first month and continued to be stronger throughout the first year compared to the longer suppression group. Who this helps: This benefits patients undergoing bone marrow transplants by potentially improving their immune recovery and overall health outcomes.

Plain English
This study looked at how well patients with multiple myeloma responded to a treatment called idecabtagene vicleucel (ide-cel) after they had already received another treatment that targeted the same cancer protein. Out of 203 patients, those who had prior treatment had a response rate of 74%, compared to 88% for those who hadn’t, and their cancer-free survival lasted an average of 3.2 months versus 9.0 months for the other group. This information is important because it shows that while ide-cel can still work after previous treatments, patients who have had those treatments may not respond as well. Who this helps: This helps patients with multiple myeloma and their doctors in making better-informed treatment choices.

Plain English
This study examined the effects of a special type of COVID-19 plasma, called Vaxplas, which comes from recovered patients who also received a vaccine. Researchers found that Vaxplas significantly reduced the amount of virus in the lungs of infected hamsters and helped them recover faster. However, it also temporarily made their illness worse and caused more lung damage because of an increase in certain immune responses. Who this helps: This research is beneficial for patients with weakened immune systems who may struggle to fight off COVID-19.

Plain English
This study looked at the structure of coronavirus spikes, which are important for how the virus enters cells and are key targets for vaccines and treatments. Researchers found that the HCoV-NL63 virus has more complex sugar structures on its spikes than the SARS-CoV-2 virus, which helps it evade the immune system more effectively. They identified a specific sugar modification at position N1242 that appears to play a crucial role in how the virus infects cells, suggesting it could be a new target for therapy. Who this helps: This helps patients at risk for HCoV-NL63 infections and the doctors treating them.

Plain English
This study looked at the effects of intravenous vitamin C on patients who received a stem cell transplant to treat blood cancers. The researchers found that patients given vitamin C had a lower risk of dying from causes other than their cancer (11% compared to 25% in those who didn't receive it), and their overall survival rate was better (82% versus 62%). This matters because it shows that vitamin C could be a simple and cost-effective way to improve health outcomes after such transplants. Who this helps: This helps patients undergoing stem cell transplants, particularly those with blood cancers.

Plain English
This study looked at the effects of intravenous vitamin C on patients who received allogeneic hematopoietic cell transplants (HCT) for blood cancers. The researchers found that patients who received vitamin C had a lower risk of death from causes other than cancer, and they had better overall survival rates compared to those who did not receive vitamin C. Specifically, patients with blood cancers like myeloid malignancies experienced even greater benefits, showing a significant improvement in survival rates. Who this helps: This helps patients undergoing stem cell transplants, particularly those with blood cancers.

Plain English
This study looked at how different schedules for administering rabbit antithymocyte globulin (ATG) affect the recovery of immune cells after a stem cell transplant. Researchers found that patients who received ATG earlier (between days -9 and -7) had better recovery of key immune cells—specifically, donor T cells—compared to those who received it later (between days -3 and -1). The early treatment led to a faster recovery of immune cells and a lower risk of serious complications, ultimately improving chances of survival. Who this helps: This helps patients undergoing stem cell transplants and their doctors in managing post-transplant care.

Plain English
This study looked at how a treatment called amotosalen/UVA pathogen reduction treatment (A/UVA-PRT) affects antibodies in convalescent plasma from people who recovered from COVID-19. Researchers found that A/UVA-PRT did not harm the effectiveness of the antibodies against SARS-CoV-2, meaning that this process can safely help produce plasma that can fight the virus. This matters because it could lead to safer blood plasma transfusions for critically ill COVID-19 patients. Who this helps: This benefits patients receiving convalescent plasma therapy for COVID-19.

Plain English
This study looked at how vaccination affects antibody levels in people who have recovered from COVID-19 and donated plasma. Researchers found that after vaccination, these donors had a significant increase in antibodies capable of neutralizing various SARS-CoV-2 variants, with levels several times higher than before vaccination. This matters because stronger antibody responses can enhance the effectiveness of convalescent plasma in helping treat COVID-19, especially as new variants emerge. Who this helps: This helps patients receiving convalescent plasma therapy.

Plain English
This study looked at 21 different tests used to detect antibodies against the SARS-CoV-2 virus, using 1,000 samples to see how well each test performed. They found that these tests had a sensitivity range of 63% to 96% and specificity of 96% to 99%, meaning some tests were very accurate while others were less reliable. This research is important because it helps determine which tests are best for monitoring the spread of COVID-19 and understanding how long antibodies last after infection or vaccination. Who this helps: This benefits patients, doctors, and public health officials who need reliable information about immunity levels in the community.

Plain English
This study looked at how grocery shopping changed during the COVID-19 pandemic by analyzing store transaction data. It found that shoppers began buying larger quantities and a wider variety of items, not just daily staples, as they stocked up and focused more on health and well-being. Understanding these changes helps retailers plan better for future crises. Who this helps: This information aids grocery retailers in understanding consumer behavior during emergencies.

Plain English
This study looked at how a protein called galectin-9 (Gal-9) affects the replication of the virus that causes COVID-19 in airway cells. Researchers found that Gal-9 significantly boosts the virus's ability to replicate and also increases inflammation in these cells, which could worsen COVID-19 symptoms. Specifically, the combination of Gal-9 and the virus triggers stronger immune responses linked to severe health issues, such as elevated levels of inflammation markers like IL-6 and TNFα. Who this helps: This research can help doctors and scientists find new treatments for patients with severe COVID-19.

Plain English
This study examined whether treating macaques infected with the coronavirus (SARS-CoV-2) with convalescent plasma from COVID-19 survivors could help reduce the virus or related lung inflammation. Researchers found that while the treatment did not lower the virus levels in the lungs, it did moderately decrease lung inflammation compared to animals that did not receive the treatment. Specifically, the treated macaques showed a significant reduction in interstitial pneumonia, but overall, the benefits were limited when compared to other treatments like monoclonal antibodies. Who this helps: This research helps doctors and researchers better understand how to use convalescent plasma for COVID-19 and similar respiratory viruses.

Plain English
This study looked at how FAF1, a protein, helps protect cells from a type of cell death called ferroptosis, which is caused by the damage of fats in the presence of iron. Researchers found that without FAF1, cells were more likely to die from ferroptosis when exposed to normal levels of certain fats, and mice on a diet high in these fats experienced liver damage. This discovery is important because it shows that FAF1 stops the harmful process that leads to cell death by keeping fats safe from oxidation. Who this helps: This helps patients with conditions linked to cell death and provides insight for doctors looking to prevent liver damage.

Plain English
This study looked at how the immune system responds to the Zika virus in people who had been infected. Researchers found that individuals who had strong activation of certain immune cells during their initial infection tended to produce high levels of neutralizing antibodies six months later, while those with a more cytotoxic immune response produced much lower antibody levels. This matters because understanding these immune responses can help develop better vaccines that effectively boost antibody production against viruses. Who this helps: This benefits vaccine researchers and patients at risk of Zika virus.

Plain English
This study looked at how the chikungunya virus, which causes joint pain and can be severe, relies on a human protein called CD81 to replicate. When CD81 was removed, the virus had a harder time replicating, while increasing CD81 levels boosted replication—indicating that CD81 is crucial for the virus's growth. This finding helps explain how chikungunya and similar viruses use our own proteins to multiply, highlighting potential targets for treatments. Who this helps: This helps researchers and doctors working on treatments for chikungunya and related viral infections.

Plain English
This study looked at new technologies to reduce the risk of infections passed through blood transfusions, specifically targeting viruses like West Nile and Zika, as well as certain parasites. They found that using techniques to reduce pathogens effectively decreased the risk of infection to safe levels, potentially allowing blood banks to keep more donors by eliminating the need for some health history questions. This could lead to an estimated 125,000 more blood donations across the country each year. Who this helps: This benefits patients in need of blood transfusions by increasing the availability of safe blood.

Plain English
This study investigated how certain thiol drugs, particularly cysteamine, might help combat COVID-19 by blocking the virus from entering cells and reducing lung inflammation. Researchers found that these drugs prevented the virus from binding to cells and significantly reduced lung inflammation in infected hamsters, but they did not lower the amount of virus in the lungs. This matters because it highlights a potential way to lessen lung damage caused by COVID-19, which could lead to better treatment options in the future. Who this helps: Patients with COVID-19 and healthcare providers treating them.

Plain English
Researchers studied how koalas interact with a virus called koala retrovirus (KoRV) and found that koalas in southern Australia, previously thought to be free of the virus, actually carry defective versions of it. In contrast, northern koalas have active virus strains that lead to high rates of diseases like lymphoma. This information is important because it suggests that southern koalas have had past exposure to KoRV, which could help in developing strategies to breed for resistance to the virus and protect koala populations. Who this helps: This benefits wildlife conservationists and researchers working to protect koalas from disease.

Plain English
This study looked at how the chikungunya virus assembles inside human cells. Researchers found 12 different stages of this assembly process, showing that immature virus structures help organize the components needed for the virus to form properly. They also discovered that certain antibodies could prevent the virus from leaving the cell by altering the spacing of its surface spikes, which is crucial for stopping the virus from spreading. Who this helps: This research can benefit doctors and scientists working on treatments for chikungunya and similar viruses.

Plain English
This paper studied a rare type of cancer called primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL) that usually affects the brain and spinal cord. It described a unique case where a young adult had a systemic relapse of this cancer, which means it spread to other parts of the body, including the adrenal glands. Understanding this type of relapse is important because there are no clear treatment guidelines available, and it could help improve future care for similar cases. Who this helps: This helps patients dealing with PCNS-DLBCL and their doctors.

Plain English
This study looked at blood donors who might have been infected with COVID-19 to see if they carried the virus in their blood and if it could be passed on through blood transfusions. Researchers found that between 9% to 15% of donors had the virus in their blood during late 2020 to early 2021, but this dropped to about 4% after the vaccine rollout. Importantly, while the virus was detected, no live infectious virus was found in the plasma of these donors, meaning blood transfusions are very unlikely to spread COVID-19. Who this helps: This helps patients needing blood transfusions and the medical professionals who provide them.

Plain English
This study looked at two patients with a type of blood cancer who received a new treatment called CAR T-cell therapy. After the treatment, both patients experienced brain problems and other side effects, and they also had temporary heart issues, specifically a drop in heart function. Understanding these heart problems is important because it helps doctors manage the risks associated with CAR T-cell therapy more effectively. Who this helps: This helps patients receiving CAR T-cell therapy and their doctors.

Plain English
This study developed a new test called SONIA that can quickly and accurately measure neutralizing antibodies against SARS-CoV-2, the virus that causes COVID-19, using a simple blood sample from a finger prick. The test showed a very high accuracy, with 91-97% sensitivity and 100% specificity compared to traditional methods. This is important because it allows for better tracking of immunity levels in the population, including how age and health conditions affect vaccine effectiveness and the response to new virus variants. Who this helps: This benefits patients, public health officials, and doctors by providing better insight into community immunity and vaccination effectiveness.

Plain English
This study looked at the effects of donated COVID-19 convalescent plasma (dCCP) on patients with COVID-19 pneumonia. Out of the recipients who received dCCP, only one patient died (6.7%) compared to six in the control group (20%), although the difference wasn't statistically significant. There were no negative side effects from the transfusions, and the study found varying levels of antibodies in the plasma, which highlights the need for better-controlled trials in the future. Who this helps: Patients with severe COVID-19 pneumonia may benefit from improved treatments based on this research.

Plain English
This study focused on finding antibodies that can stop alphaviruses, like chikungunya and Mayaro, from escaping cells after they have replicated. Researchers developed a special high-throughput testing system that identified several antibodies with strong abilities to prevent the release of these viruses. For example, they discovered antibodies from immune individuals that showed effective results in blocking viral egress, which is an important step in controlling infections. Who this helps: This benefits patients at risk for alphavirus infections, as well as doctors looking for effective treatments.

Plain English
Researchers studied the effects of convalescent plasma (blood from recovered COVID-19 patients) on Rhesus macaques infected with the SARS-CoV-2 virus. They found that giving the plasma within a day of infection did not reduce the amount of virus in the animals' bodies or improve their health in any measurable way. This matters because it suggests that using convalescent plasma as a treatment for COVID-19, even when given early, may not be effective, which can guide future treatment strategies. Who this helps: This helps doctors and researchers looking for effective COVID-19 treatments.